Literature DB >> 21671508

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

Vibeke Guldbrand Rasmussen1, Karen Østergaard, Erik Dupont, Steen Hvitfeldt Poulsen.   

Abstract

OBJECTIVES: Several observational studies suggest an association between treatment with ergoline-derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta-analysis.
METHODS: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline-treated patients with Parkinson's disease were considered for a meta-analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated.
RESULTS: The pooling of data from well-designed observational studies documented that both pergolide (RR = 3.05 [1.71-5.44]) and cabergoline (RR = 6.38 [3.17-12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure.
CONCLUSIONS: The present meta-analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671508     DOI: 10.1002/mds.23470

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis.

Authors:  Jacqueline H Fortier; Beatrice Pizzarotti; Richard E Shaw; Robert J Levy; Giovanni Ferrari; Juan Grau
Journal:  Heart       Date:  2019-05-25       Impact factor: 5.994

Review 2.  Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.

Authors:  R De Vecchis; C Esposito; C Ariano
Journal:  Herz       Date:  2013-06-08       Impact factor: 1.443

3.  Pergolide block of the cloned Kv1.5 potassium channels.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-05       Impact factor: 3.000

Review 4.  Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.

Authors:  Tanja Tran; James M Brophy; Samy Suissa; Christel Renoux
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

5.  Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.

Authors:  Florence van Hunsel; Laura Peters; Helga Gardarsdottir; Agnes Kant
Journal:  Drug Saf       Date:  2021-02-19       Impact factor: 5.606

6.  The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials.

Authors:  Chunxiao Wu; Hongji Guo; Yingshan Xu; Luping Li; Xinyu Li; Chunzhi Tang; Dongfeng Chen; Meiling Zhu
Journal:  Front Aging Neurosci       Date:  2022-04-22       Impact factor: 5.750

7.  Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease.

Authors:  Yasir Hasan Siddique; Wasi Khan; Ambreen Fatima; Smita Jyoti; Saba Khanam; Falaq Naz; Fahad Ali; Braj Raj Singh; Alim Hussain Naqvi
Journal:  Dis Model Mech       Date:  2015-11-05       Impact factor: 5.758

Review 8.  Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology.

Authors:  Josip Anđelo Borovac
Journal:  Yale J Biol Med       Date:  2016-03-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.